Literature DB >> 21728021

First case of posterior reversible encephalopathy syndrome associated with vinflunine.

Carole Helissey1, Cyrus Chargari, Marion Lahutte, Damien Ricard, Lionel Vedrine, Bernard Ceccaldi, Sylvestre Le Moulec.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21728021     DOI： 10.1007/s10637-011-9712-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  10 in total

Review 1.  Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.

Authors:  Qisi Wu; Christian Marescaux; Valérie Wolff; Mi-Young Jeung; Romain Kessler; Valérie Lauer; Yangmei Chen
Journal:  Eur Neurol       Date:  2010-08-12       Impact factor: 1.710

Review 2.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

Review 3.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

Review 4.  CNS complications of radiotherapy and chemotherapy.

Authors:  Carole Soussain; Damien Ricard; John R Fike; Jean-Jacques Mazeron; Dimitri Psimaras; Jean-Yves Delattre
Journal:  Lancet       Date:  2009-11-07       Impact factor: 79.321

Review 5.  Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.

Authors:  Holger Gerullis; Thorsten Ecke; Christoph Eimer; Mohamed Wishahi; Thomas Otto
Journal:  Anticancer Drugs       Date:  2011-01       Impact factor: 2.248

Review 6.  Vinflunine: a new microtubule inhibitor agent.

Authors:  Jaafar Bennouna; Jean-Pierre Delord; Mario Campone; Laurent Nguyen
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

7.  Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings.

Authors:  Alexander M McKinney; James Short; Charles L Truwit; Zeke J McKinney; Osman S Kozak; Karen S SantaCruz; Mehmet Teksam
Journal:  AJR Am J Roentgenol       Date:  2007-10       Impact factor: 3.959

8.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

9.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Authors:  Joaquim Bellmunt; Christine Théodore; Tomasz Demkov; Boris Komyakov; Lisa Sengelov; Gedske Daugaard; Armelle Caty; Joan Carles; Agnieszka Jagiello-Gruszfeld; Oleg Karyakin; François-Michel Delgado; Patrick Hurteloup; Eric Winquist; Nassim Morsli; Yacine Salhi; Stéphane Culine; Hans von der Maase
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

10.  Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.

Authors:  Anita Rajasekhar; Thomas J George
Journal:  Oncologist       Date:  2007-11
  10 in total
  2 in total

1.  Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review.

Authors:  Changqing Xie; Vovanti T Jones
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

Review 2.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.